Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gerhard Pölzl
  • Shadab Allipour Birgani
  • Josep Comín-Colet
  • Juan F Delgado
  • Francesco Fedele
  • Martín Jesús García-Gonzáles
  • Finn Gustafsson
  • Josep Masip
  • Zoltán Papp
  • Stefan Störk
  • Hanno Ulmer
  • Bojan Vrtovec
  • Gerhard Wikström
  • Johann Altenberger
View graph of relations

Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, international, multicentre trial that will explore the efficacy and safety of intermittent levosimendan therapy, in addition to optimized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treatment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospitalization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints include changes in HF symptoms and functional status at 14 weeks.

Original languageEnglish
JournalESC Heart Failure
Volume6
Issue number1
Pages (from-to)174-181
ISSN2055-5822
DOIs
Publication statusPublished - 2019

    Research areas

  • Advanced heart failure, Global rank endpoint, Hospitalization, Levosimendan, N-terminal pro-brain natriuretic peptide, Randomized controlled trial, Double-Blind Method, Drug Administration Schedule, Follow-Up Studies, Humans, Patient Discharge, Stroke Volume/physiology, Treatment Outcome, Cardiotonic Agents/administration & dosage, Dose-Response Relationship, Drug, Heart Failure/drug therapy, Simendan/administration & dosage, Infusions, Intravenous

ID: 56235716